Seek Returns logo

BMRN vs. IDXX: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BMRN and IDXX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolBMRNIDXX
Company NameBioMarin Pharmaceutical Inc.IDEXX Laboratories, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyHealth Care Equipment & Supplies
Market Capitalization11.26 billion USD51.27 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJuly 26, 1999June 21, 1991
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of BMRN and IDXX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BMRN vs. IDXX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBMRNIDXX
5-Day Price Return1.02%1.23%
13-Week Price Return0.95%24.08%
26-Week Price Return-14.05%41.54%
52-Week Price Return-34.81%32.39%
Month-to-Date Return1.40%19.94%
Year-to-Date Return-10.76%55.01%
10-Day Avg. Volume1.76M0.43M
3-Month Avg. Volume2.14M0.64M
3-Month Volatility25.78%60.22%
Beta0.341.60

Profitability

Return on Equity (TTM)

BMRN

11.48%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

In the upper quartile for the Biotechnology industry, BMRN’s Return on Equity of 11.48% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

IDXX

64.42%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

BMRN vs. IDXX: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

BMRN

21.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

A Net Profit Margin of 21.45% places BMRN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

IDXX

24.41%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

IDXX’s Net Profit Margin of 24.41% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

BMRN vs. IDXX: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

BMRN

25.33%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

An Operating Profit Margin of 25.33% places BMRN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

IDXX

31.09%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

IDXX’s Operating Profit Margin of 31.09% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

BMRN vs. IDXX: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

SymbolBMRNIDXX
Return on Equity (TTM)11.48%64.42%
Return on Assets (TTM)9.24%29.89%
Net Profit Margin (TTM)21.45%24.41%
Operating Profit Margin (TTM)25.33%31.09%
Gross Profit Margin (TTM)79.56%61.54%

Financial Strength

Current Ratio (MRQ)

BMRN

5.56

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

BMRN’s Current Ratio of 5.56 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

IDXX

1.11

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BMRN vs. IDXX: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BMRN

0.10

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

IDXX

0.76

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

IDXX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

BMRN vs. IDXX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

BMRN

-21.18

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

IDXX

49.24

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

BMRN vs. IDXX: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

SymbolBMRNIDXX
Current Ratio (MRQ)5.561.11
Quick Ratio (MRQ)3.600.75
Debt-to-Equity Ratio (MRQ)0.100.76
Interest Coverage Ratio (TTM)-21.1849.24

Growth

Revenue Growth

BMRN vs. IDXX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BMRN vs. IDXX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BMRN vs. IDXX: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BMRN vs. IDXX: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

SymbolBMRNIDXX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

BMRN

17.06

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

BMRN’s P/E Ratio of 17.06 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

IDXX

51.66

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

IDXX’s P/E Ratio of 51.66 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

BMRN vs. IDXX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

BMRN

3.66

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.66 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

IDXX

12.61

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

With a P/S Ratio of 12.61, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

BMRN vs. IDXX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

BMRN

1.75

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

BMRN’s P/B Ratio of 1.75 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

IDXX

29.57

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

BMRN vs. IDXX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

SymbolBMRNIDXX
Price-to-Earnings Ratio (TTM)17.0651.66
Price-to-Sales Ratio (TTM)3.6612.61
Price-to-Book Ratio (MRQ)1.7529.57
Price-to-Free Cash Flow Ratio (TTM)16.2265.76